Partner with WeHealth Digital Medicine

Does your digital solution tackle chronic illness
and upgrade the practice of medicine?

Would collaborating with experts within the treatment environment and a global life sciences company accelerate product development and commercialization?  
If your answer is yes, let's connect!

Through its collaboration, UCSF’s Center for Digital Health Innovation (CDHI) and WeHealth Digital Medicine, the eHealth department of the Servier Group, are looking for early stage companies developing digital health solutions to  prevent, diagnose, monitor, treat and predict the evolution of diseases in the following five therapeutic areas:
  • Cancer
  • Cardiovascular diseases
  • Diabetes and its related complications
  • Neuropsychiatric diseases
  • Immune-inflammatory diseases
Between June and December 2019, WeHealth Digital Medicine will be seeking to establish an agreement for co-creation, funding and mentorship with one to two early stage companies.

About WeHealth Digital Medicine

Launched in November 2016, WeHealth Digital Medicine, the eHealth department of the Servier Group, aims to improve the daily lives of patients and health professionals alike using digital means. WeHealth Digital Medicine proposes innovative digital and connected solutions and services by making the most of collected data, to ensure better individual monitoring of the patient and to better prevent and predict the evolution of disease. In an open innovative approach, WeHealth Digital Medicine identifies the most promising start-ups in e-health, in France and internationally, to co-develop solutions. In this way, WeHealth Digital Medicine contributes to the creation of an ecosystem of partners to facilitate and accelerate the development, industrialization and distribution of innovations and to render them accessible to the greatest number.

Submit Your Interest Form Now

Our selection criteria

 Companies who apply below will be evaluated with the qualifying candidates invited to present on xxx and the final selection occurring on or before September 2019. Our selection criteria includes:
  • Series A to Series C companies only
  • Interested company to have a digital health solution (either diagnosis tool, monitoring tool, clinical decision support or digital therapeutic except wellness solution) that impacts the patient journey in at least one of the target disease areas listed above
  • The digital solution has the potential for global impact and dissemination within a three year timeframe